Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate

John L. Andreassi, Patrick W. Bilder, Matthew W. Vetting, Steven L. Roderick, Thomas S. Leyh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate (DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase (SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 Å and in complex with DPM·Mg2+ in the active-site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog (mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complexlike form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK-binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency. Published by Cold Spring Harbor Laboratory Press.

Original languageEnglish (US)
Pages (from-to)983-989
Number of pages7
JournalProtein Science
Volume16
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

mevalonate kinase
Streptococcus pneumoniae
Crystal structure
Lead compounds
Mevalonic Acid
Terpenes
Pathogens
Ports and harbors
Isoenzymes
Biosynthetic Pathways
Phosphotransferases
Nucleotides
Adenosine Triphosphate
Health
Catalytic Domain
Enzymes

Keywords

  • Allosteric inhibitor
  • Antimicrobial target
  • Crystal structure
  • Diphosphomevalonate
  • GHMP kinase
  • Mevalonate deficiency
  • Mevalonate kinase
  • Streptococcus pnuemoniae

ASJC Scopus subject areas

  • Biochemistry

Cite this

Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate. / Andreassi, John L.; Bilder, Patrick W.; Vetting, Matthew W.; Roderick, Steven L.; Leyh, Thomas S.

In: Protein Science, Vol. 16, No. 5, 05.2007, p. 983-989.

Research output: Contribution to journalArticle

Andreassi, John L. ; Bilder, Patrick W. ; Vetting, Matthew W. ; Roderick, Steven L. ; Leyh, Thomas S. / Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate. In: Protein Science. 2007 ; Vol. 16, No. 5. pp. 983-989.
@article{048f59daf81c4f04be5b0da281798c83,
title = "Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate",
abstract = "Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate (DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase (SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 {\AA} and in complex with DPM·Mg2+ in the active-site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog (mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complexlike form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK-binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency. Published by Cold Spring Harbor Laboratory Press.",
keywords = "Allosteric inhibitor, Antimicrobial target, Crystal structure, Diphosphomevalonate, GHMP kinase, Mevalonate deficiency, Mevalonate kinase, Streptococcus pnuemoniae",
author = "Andreassi, {John L.} and Bilder, {Patrick W.} and Vetting, {Matthew W.} and Roderick, {Steven L.} and Leyh, {Thomas S.}",
year = "2007",
month = "5",
doi = "10.1110/ps.072755707",
language = "English (US)",
volume = "16",
pages = "983--989",
journal = "Protein Science",
issn = "0961-8368",
publisher = "Cold Spring Harbor Laboratory Press",
number = "5",

}

TY - JOUR

T1 - Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate

AU - Andreassi, John L.

AU - Bilder, Patrick W.

AU - Vetting, Matthew W.

AU - Roderick, Steven L.

AU - Leyh, Thomas S.

PY - 2007/5

Y1 - 2007/5

N2 - Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate (DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase (SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 Å and in complex with DPM·Mg2+ in the active-site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog (mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complexlike form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK-binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency. Published by Cold Spring Harbor Laboratory Press.

AB - Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate (DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase (SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 Å and in complex with DPM·Mg2+ in the active-site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog (mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complexlike form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK-binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency. Published by Cold Spring Harbor Laboratory Press.

KW - Allosteric inhibitor

KW - Antimicrobial target

KW - Crystal structure

KW - Diphosphomevalonate

KW - GHMP kinase

KW - Mevalonate deficiency

KW - Mevalonate kinase

KW - Streptococcus pnuemoniae

UR - http://www.scopus.com/inward/record.url?scp=34247609151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247609151&partnerID=8YFLogxK

U2 - 10.1110/ps.072755707

DO - 10.1110/ps.072755707

M3 - Article

VL - 16

SP - 983

EP - 989

JO - Protein Science

JF - Protein Science

SN - 0961-8368

IS - 5

ER -